JP2002536387A5 - - Google Patents

Download PDF

Info

Publication number
JP2002536387A5
JP2002536387A5 JP2000598098A JP2000598098A JP2002536387A5 JP 2002536387 A5 JP2002536387 A5 JP 2002536387A5 JP 2000598098 A JP2000598098 A JP 2000598098A JP 2000598098 A JP2000598098 A JP 2000598098A JP 2002536387 A5 JP2002536387 A5 JP 2002536387A5
Authority
JP
Japan
Prior art keywords
carrageenan
agarose
polymer
effective amount
acrylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000598098A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002536387A (ja
Filing date
Publication date
Priority claimed from US09/250,123 external-priority patent/US6159491A/en
Application filed filed Critical
Publication of JP2002536387A publication Critical patent/JP2002536387A/ja
Publication of JP2002536387A5 publication Critical patent/JP2002536387A5/ja
Pending legal-status Critical Current

Links

JP2000598098A 1999-02-12 2000-02-08 持続的放出生体接着膣投与剤 Pending JP2002536387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/250,123 US6159491A (en) 1999-02-12 1999-02-12 Prolonged release bioadhesive vaginal gel dosage form
US09/250,123 1999-02-12
PCT/US2000/003237 WO2000047144A1 (en) 1999-02-12 2000-02-08 Prolonged release bioadhesive vaginal gel dosage form

Publications (2)

Publication Number Publication Date
JP2002536387A JP2002536387A (ja) 2002-10-29
JP2002536387A5 true JP2002536387A5 (enExample) 2007-04-05

Family

ID=22946381

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000598098A Pending JP2002536387A (ja) 1999-02-12 2000-02-08 持続的放出生体接着膣投与剤

Country Status (12)

Country Link
US (1) US6159491A (enExample)
EP (1) EP1150630A4 (enExample)
JP (1) JP2002536387A (enExample)
KR (1) KR20010102088A (enExample)
CN (1) CN1222279C (enExample)
AU (1) AU762677B2 (enExample)
BR (1) BR0008137A (enExample)
CA (1) CA2362561A1 (enExample)
HK (1) HK1045934B (enExample)
MX (1) MXPA01008093A (enExample)
WO (1) WO2000047144A1 (enExample)
ZA (1) ZA200106640B (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6835717B2 (en) * 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
US7220414B2 (en) 2000-09-06 2007-05-22 A.P. Pharma, Inc. Degradable polyacetal polymers
GB2366794A (en) * 2000-09-13 2002-03-20 Procter & Gamble Process for making a foam component
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
EP1343492B1 (en) * 2000-11-22 2006-02-01 Rxkinetix, Inc. Treatment of mucositis
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US7709026B2 (en) * 2001-10-29 2010-05-04 Columbia Laboratories, Inc. Low concentration of peroxide for treating or preventing vaginal infections
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
CA2504283A1 (en) * 2002-10-31 2004-05-21 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
ATE461681T1 (de) * 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
RU2236851C1 (ru) * 2003-06-16 2004-09-27 Красноярская государственная медицинская академия Способ местного лечения бактериального вагиноза
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
ITMI20031640A1 (it) 2003-08-08 2005-02-09 Mipharm S P A Base per gel bioadesivi.
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
US20050202038A1 (en) * 2004-03-10 2005-09-15 Green Roger E. Composition and method for minimizing residual fecal matter in the perianal area
US7276486B2 (en) * 2004-03-15 2007-10-02 Kimberly-Clark Worldwide, Inc. Compositions for vaginal treatment
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
ES2608005T3 (es) * 2004-09-22 2017-04-05 Ge Healthcare Bioprocess R&D Ab Método para preparar una matriz cromatográfica
FR2876581B1 (fr) * 2004-10-20 2007-05-18 Interpharm Dev Composition bioadhesive a liberation programmee
AU2012200105B2 (en) * 2004-10-20 2014-11-20 Care & Pharma Perspectives Sa Bioadhesive composition with programmed release
US20060106117A1 (en) * 2004-11-12 2006-05-18 Kimberly-Clark Worldwide, Inc. Compound and method for prevention and/or treatment of vaginal infections
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060292102A1 (en) * 2004-12-10 2006-12-28 Roman Stephen B Thixotropic personal lubricant
CN1302764C (zh) * 2005-01-10 2007-03-07 凌沛学 一种妇科用药阴道凝胶片
US20060223765A1 (en) * 2005-03-30 2006-10-05 Kimberly-Clark Worldwide, Inc. Method for inhibiting and/or treating vaginal infection
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
AU2006320538B2 (en) * 2005-11-30 2013-07-04 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8399012B2 (en) * 2006-04-17 2013-03-19 Kimberly-Clark Worldwide, Inc. Degradable therapeutic delivery device
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
US11058699B2 (en) * 2008-07-01 2021-07-13 Wisconsin Alumni Research Foundation Method and compositions for inhibition of double stranded DNA viruses
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
MX2013012745A (es) * 2011-05-02 2014-12-05 Aptalis Pharmatech Inc Composiciones en forma de comprmido de disolución rápida para administración vaginal.
US9301921B2 (en) * 2012-04-05 2016-04-05 Gavis Pharmaceuticals, Llc Laxative gel composition
US9642794B2 (en) * 2014-08-18 2017-05-09 Tamir Biotechnology, Inc. Antiviral pharmaceutical for topical administration
US10835598B2 (en) * 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
EP3442501A1 (en) 2016-04-15 2019-02-20 Fairhaven Health, LLC Compositions and methods for maintaining or enhancing homeostasis or function of female lower reproductive tract

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
ATE151286T1 (de) * 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
US4983392A (en) * 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US5225196A (en) * 1983-11-14 1993-07-06 Columbia Laboratories, Inc. Bioadhesive compositions and methods of treatment therewith
US4795436A (en) * 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US4707362A (en) * 1985-02-15 1987-11-17 Biotek, Inc. Sustained release composition
PL149493B1 (en) * 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
GB8520664D0 (en) * 1985-08-17 1985-09-25 Euro Celtique Sa Suppository
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4983393A (en) * 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
US5624675A (en) * 1989-06-06 1997-04-29 Kelly; Patrick D. Genital lubricants containing zinc salts to reduce risk of HIV infection
JPH05502465A (ja) * 1989-08-28 1993-04-28 ファーマスーティカル　デリバリー　システムズ 治療薬剤の制御放出のために有用な生体内で分解し得るポリマー
DK0431719T3 (da) * 1989-10-31 1995-02-27 Columbia Lab Inc Vaginalt vævsbefugtende præparat
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
IT1250421B (it) * 1991-05-30 1995-04-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5472711A (en) * 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
CA2105887C (en) * 1992-09-10 2004-03-16 Peter Britton Bioerodible device for administering active ingredients
US5330761A (en) * 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
FR2710265B1 (fr) * 1993-09-22 1995-10-20 Adir Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs.
GB9414699D0 (en) * 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
US5612052A (en) * 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
AU5782500A (en) * 1999-07-06 2001-01-22 Procter & Gamble Company, The Pre-formed, self-adhesive sheet devices suitable for topical application

Similar Documents

Publication Publication Date Title
JP2002536387A5 (enExample)
WO2000019985A3 (en) New sustained release oral formulations
AU2001253479A1 (en) Targeted therapeutic agent release devices and methods of making and using the same
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
IL152294A0 (en) Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
HUP0301465A3 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2001263264A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP2004525194A5 (enExample)
HUP0301083A3 (en) Synergistical herbicide composition and use thereof
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
CA2457361A1 (en) Opioid agonist formulations with releasable and sequestered antagonist
WO2001054679A3 (en) Transdermal composition containing an anesthetic and a vasodilator agent
IL152473A0 (en) Topical anesthetic/opioid formulations and uses thereof
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
NZ531404A (en) Plaster for the treatment of dysfunctions and disorders of nails, comprising sertaconazole
NO20002129L (no) Indazol-bioisoster erstatning av catechol i terapeutiske aktive forbindelser
WO2004064815A8 (en) Oral dosage formulation
PL348109A1 (en) Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
AU4451501A (en) Therapeutic anti-inflammatory and analgesic composition containing selective cox-2 inhibitor drugs for use transdermally and a process for the manufacture thereof
JP2003508328A5 (enExample)
AU2001248336A1 (en) Controlled release oral solid forms containing mesalazine as active agent
JP2002522501A5 (enExample)
EE05174B1 (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks
MY128759A (en) Oral controlled release formulations